# Vinay Prasad Type: Person Source: GetYourBrief — https://getyourbrief.com/entity/vinay-prasad Canonical HTML page: https://getyourbrief.com/entity/vinay-prasad ## Timeline - **2026-03-15**: Public Criticism — Major editorials highlight the FDA's 'erratic' behavior as a threat to the broader innovation ecosystem. - **2026-03-15**: Market Impact — Moderna's valuation remains at roughly 10% of its pandemic-era high amid regulatory uncertainty. - **2026-03-15**: Industry Warning — Editorials warn that erratic FDA behavior is a threat to biotech innovation. - **2026-02-03**: Refusal to File — FDA's Vinay Prasad issues a formal refusal to review the flu vaccine application. - **2026-02-03**: Refusal to File — Senior regulator Vinay Prasad refuses to review Moderna's flu vaccine application, citing trial design concerns. - **2026-02-03**: Refusal to File — Senior regulator Vinay Prasad issues a rare letter refusing to review Moderna's flu vaccine application. - **2026-02-03**: Refusal to File — FDA regulator Vinay Prasad refuses to review Moderna's flu vaccine application. - **2026-02-03**: Application Refusal — FDA senior regulator Vinay Prasad issues a formal refusal to review the flu vaccine application. - **2025-12-31**: Grants Rescinded — The administration pulls back hundreds of millions in funding for mRNA-based research projects. - **2025-12-31**: Grants Rescinded — White House rescinds hundreds of millions in mRNA research grants by year-end. - **2025-12-01**: Grants Rescinded — The White House rescinds hundreds of millions in mRNA research grants as political rhetoric shifts. - **2025-11-10**: Grant Rescissions — The White House rescinds hundreds of millions in mRNA research funding. - **2025-08-20**: Workaround Support — FDA officials reportedly signal acceptance of Moderna's alternative trial data submission. - **2025-08-15**: Workaround Supported — FDA officials appear to support Moderna's plan to use data from a smaller trial as a workaround for control group concerns. - **2025-08-15**: Regulatory Alignment — FDA officials reportedly signal support for Moderna's trial data workaround. ## Recent coverage (5 stories, network-wide) ### Regulatory Volatility: FDA’s Moderna Rejection Signals New Risk for Biotech 2026-03-16 00:17:53 · Sector: startups · Sentiment: Negative · Impact: 8/10 · Sources: 2 Moderna faces a significant regulatory setback as the FDA refuses to review its new flu vaccine, citing trial design flaws despite previous guidance. This shift reflects a broader, politically charged environment that threatens to destabilize the venture-backed biotech ecosystem. Full story: https://getstartupbrief.com/story/fda-moderna-regulatory-volatility-biotech-innovation ### FDA Regulatory Shift Threatens Biotech Innovation and Moderna's Recovery 2026-03-16 00:17:19 · Sector: finance · Sentiment: Negative · Impact: 8/10 · Sources: 2 Moderna Inc. faces a critical juncture as the FDA's increasingly erratic regulatory stance and shifting White House sentiment jeopardize the future of mRNA technology. A rare refusal to review the company's flu vaccine data highlights a growing rift between the agency and the industry it oversees, threatening the predictability required for biotech investment. Full story: https://getfinancebrief.com/story/fda-regulatory-shift-moderna-innovation-threat ### FDA Regulatory Volatility and Political Shifts Threaten Moderna’s mRNA Pipeline 2026-03-16 00:16:43 · Sector: bio · Sentiment: Negative · Impact: 8/10 · Sources: 2 Moderna faces a critical setback after the FDA issued a rare refusal to review its flu vaccine application, signaling a shift in the regulatory and political climate for mRNA technology. This development, coupled with rescinded federal grants and a 90% decline in market value from pandemic peaks, highlights growing friction between the biotech industry and federal oversight. Full story: https://getbiobrief.com/story/fda-moderna-mrna-regulatory-threat ### FDA's Regulatory Shift Signals New Era of Uncertainty for mRNA Innovation 2026-03-16 00:16:10 · Sector: health · Sentiment: Negative · Impact: 8/10 · Sources: 2 The FDA's recent refusal to review Moderna's flu vaccine application marks a significant pivot in the regulatory environment for mRNA technology. This shift, characterized by increasing political pressure and unpredictable oversight, threatens to stifle the very innovation that defined the pandemic response. Full story: https://gethealthbrief.com/story/fda-moderna-mrna-regulatory-uncertainty ### FDA Regulatory Shifts and Moderna's Flu Vaccine Setback Threaten Innovation 2026-03-16 00:09:34 · Sector: legal · Sentiment: Negative · Impact: 8/10 · Sources: 2 The FDA's rare 'refusal to file' regarding Moderna's mRNA flu vaccine signals a pivot from pandemic-era collaboration to a more adversarial regulatory environment. This unpredictability, combined with rescinded federal grants and a 90% decline in market value, highlights the growing legal and compliance risks for biotech firms. Full story: https://getlegalbrief.com/story/fda-moderna-regulatory-risk-analysis --- This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.